NVS May 2024 90.000 call
| Previous close | 7.30 |
| Open | 7.30 |
| Bid | 9.70 |
| Ask | 9.90 |
| Strike | 90.00 |
| Expiry date | 2024-05-17 |
| Day's range | 7.30 - 7.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 419 |
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
